Valuation Scholar Rock Holding Corporation
Stocks
SRRK
US80706P1030
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
04:00:00 03/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 46.81 USD | +1.41% |
|
-3.74% | +6.27% |
| 09-30 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
| 09-26 | Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says | MT |
Company Valuation: Scholar Rock Holding Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 872.1 | 467.6 | 1,356 | 4,046 | 4,493 | 5,701 | - | - |
| Change | - | -46.39% | 190.08% | 198.32% | 11.06% | 26.87% | - | - |
| Enterprise Value (EV) 1 | 709.3 | 414 | 1,304 | 3,918 | 4,270 | 5,384 | 5,290 | 5,311 |
| Change | - | -41.63% | 215.07% | 200.38% | 8.97% | 26.11% | -1.74% | 0.39% |
| P/E | -6.92x | -4x | -9.45x | -17.5x | -13.4x | -14.3x | -18x | -35.9x |
| PBR | 5.3x | 2.07x | 6.96x | 11x | 20.6x | 21.5x | 18.9x | 20.1x |
| PEG | - | 0.1x | 0.8x | -0.7x | -0.4x | 30.18x | 0.9x | 0.7x |
| Capitalization / Revenue | 46.3x | 14.1x | - | - | - | 838x | 40.3x | 14.4x |
| EV / Revenue | 37.7x | 12.5x | - | - | - | 792x | 37.4x | 13.4x |
| EV / EBITDA | -5.57x | - | - | - | -11.1x | -12.5x | -17.1x | -46.2x |
| EV / EBIT | -5.46x | -3.08x | -7.62x | -15.5x | -11.1x | -12.4x | -15.3x | -33.3x |
| EV / FCF | -5.37x | -3.1x | -8.98x | -19.5x | -14.2x | -19.4x | -24.1x | -63x |
| FCF Yield | -18.6% | -32.3% | -11.1% | -5.13% | -7.04% | -5.14% | -4.14% | -1.59% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.59 | -2.26 | -1.99 | -2.47 | -3.29 | -3.274 | -2.603 | -1.304 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 18.82 | 33.19 | - | - | - | 6.802 | 141.4 | 395 |
| EBITDA 1 | -127.3 | - | - | - | -383 | -429.2 | -308.8 | -114.9 |
| EBIT 1 | -129.9 | -134.4 | -171.3 | -252.1 | -384.6 | -435.9 | -345.9 | -159.5 |
| Net income 1 | -131.8 | -134.5 | -165.8 | -246.3 | -377.9 | -428.5 | -359.6 | -177.4 |
| Net Debt 1 | -162.8 | -53.53 | -51.84 | -127.7 | -223.8 | -316.5 | -410.4 | -390 |
| Reference price 2 | 24.84 | 9.05 | 18.80 | 43.22 | 44.05 | 46.81 | 46.81 | 46.81 |
| Nbr of stocks (in thousands) | 35,108 | 51,663 | 72,143 | 93,615 | 102,007 | 121,785 | - | - |
| Announcement Date | 7/3/22 | 7/3/23 | 19/3/24 | 27/2/25 | 3/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -14.3x | 791.53x | -12.55x | -.--% | 5.7B | |
| 21.73x | 7.71x | 15.48x | 1.37% | 74.16B | |
| 29.82x | 8.57x | 26.7x | 0.04% | 57.39B | |
| 32.98x | 5.93x | 17.77x | 0.98% | 47.64B | |
| -21.31x | 230.81x | -22.97x | -.--% | 44.29B | |
| 33.26x | 3.23x | 13.97x | -.--% | 42.5B | |
| 46.77x | 5.41x | 29.66x | -.--% | 40.71B | |
| 27.63x | 7.93x | 20.48x | 0.41% | 30.97B | |
| 32.99x | 7.05x | 18.3x | -.--% | 28.53B | |
| -15.1x | 5.68x | -7.14x | -.--% | 24.34B | |
| Average | 17.45x | 107.38x | 9.97x | 0.28% | 39.62B | |
| Weighted average by Cap. | 21.75x | 42.96x | 13.18x | 0.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SRRK Stock
- Valuation Scholar Rock Holding Corporation
Select your edition
All financial news and data tailored to specific country editions
